Craig Fraser, CEO of Windtree Therapeutics, Inc., was recently interviewed by Benzinga.
Windtree is advancing late-stage interventions for cardiovascular disorders to treat patients in moments of crisis.
Using new scientific and clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with the ability to activate SERCA2a, which is critical in patients experiencing acute cardiac events. Its lead candidate, istaroxime, is being developed as a first-in-class treatment for cardiogenic shock and acute heart failure.
Mr. Frasier discussed his company’s recent deal with Lee’s Pharmaceuticals which will help Windtree to develop and commercialize its therapies.
